Evidence map›Paper›PMID 36839799›Full record

ArticlePharmaceutics2023

Development of a Library of Disulfide Bond-Containing Cationic Lipids for mRNA Delivery.

Zhigao Shen, Cong Liu, Ziqian Wang, Fengfei Xie, Xingwu Liu, Lingkai Dong, Xuehua Pan, Chen Zeng, Peng George Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Zhigao ShenDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Cong LiuDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Ziqian WangDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Fengfei XieDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Xingwu LiuDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Lingkai DongDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Xuehua PanDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Chen ZengDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.
Peng George WangDepartment of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China.ORCID 0000-0003-3335-6794
Southern University of Science and Technology · CN

Funding

China Postdoctoral Science Foundation 2021M691436Natural Science Foundation of China 22107044Shenzhen Science and Technology Program KQTD20200909113758004
6 · The paper itself

Abstract

Lipid nanoparticles (LNPs) are the commonly used delivery tools for messenger RNA (mRNA) therapy and play an indispensable role in the success of COVID-19 mRNA vaccines. Ionizable cationic lipids are the most important component in LNPs. Herein, we developed a series of new ionizable lipids featuring bioreducible disulfide bonds, and constructed a library of lipids derived from dimercaprol. LNPs prepared from these ionizable lipids could be stored at 4 °C for a long term and are non-toxic toward HepG2 and 293T cells. In vivo experiments demonstrated that the best C4S18A formulations, which embody linoleoyl tails, show strong firefly luciferase (Fluc) mRNA expression in the liver and spleen via intravenous (IV) injection, or at the local injection site via intramuscular injection (IM). The newly designed ionizable lipids can be potentially safe and high-efficiency nanomaterials for mRNA therapy.

Indexed as

disulfide bondlipid nanoparticlesmRNA delivery

Identifiers

PMID36839799
PMCPMC9961079
OpenAlexW4318832988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.